Study on the efficacy of immunotherapy combined with local treatment in elderly patients with advanced NSCLC
10.3969/j.issn.1673-9701.2025.11.010
- VernacularTitle:免疫治疗联合局部治疗在老年晚期NSCLC患者中的疗效研究
- Author:
Yunye MAO
1
;
An WANG
;
Xiangwei GE
;
Jinzhao ZHAI
;
Tao LI
;
Jinliang WANG
Author Information
1. 解放军总医院第五医学中心肿瘤医学部肿瘤内科,北京 100071;解放军医学院,北京 100853
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Immunotherapy;
Local treatment;
Elderly patients
- From:
China Modern Doctor
2025;63(11):39-41
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of immunotherapy combined with local treatment in elderly patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 164 elderly patients with advanced NSCLC admitted in Chinese PLA General Hospital from January 2018 to October 2022 were selected as subjects.According to whether they have received immunotherapy combined with local treatment,they were divided into local treatment group(n=82)and non-local treatment group(n=82).The primary endpoint was overall survival(OS),while secondary endpoints included progression-free survival(PFS),objective response rate(ORR),and disease control rate(DCR).Cox proportional hazard models were applied to assess prognostic factors.Results The median OS in local treatment group was superior to non-local treatment group.Multivariate analysis confirmed that Eastern Cooperative Oncology Group performance status score ≥ 2 points,bone metastasis,and pleural effusion were independent poor prognostic factors.Conclusion The combination of immunotherapy and local treatment may provide OS of elderly patients with advanced NSCLC.
